Abstract
Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin’s lymphomas resulting from clonal expansion and localization of malignant T-lymphocytes to the skin. CTCL cells have defective apoptosis. Signal transducers and activators of transcription (STAT) are a family of transcription factors known to play important roles in the development and progression of several human cancers by promoting cell proliferation and protecting against apoptosis. In this study, we investigated the specific role of STAT3, a major component of the STAT family, in growth and survival of human CTCL cell line Hut78. Western immunoblot analysis showed elevated expression of STAT3 and phospho-STAT3(Y705) in human CTCL cells as compared to freshly isolated peripheral blood lymphocytes (PBLs). Specific knockdown of STAT3 expression in Hut78 cells by RNA interference induced morphological and biochemical changes indicating apoptotic cell death. Moreover, STAT3 inhibition downregulated the expression of Bcl2 family of anti-apoptotic gene Bcl-xL. These observations suggest that STAT3 is required for the survival of CTCL cells and strongly indicate that targeting STAT3 using siRNA techniques may serve a novel therapeutic strategy for the treatment of CTCL.
[1] Siegel, R.S. and Kuzel, T.M. Cutaneous T-cell lymphoma/leukemia. Curr. Trends Options Oncol. 1 (2000) 43–50. http://dx.doi.org/10.1007/s11864-000-0014-010.1007/s11864-000-0014-0Search in Google Scholar
[2] Kotz, E.A., Anderson, D. and Thiers, B.H. Cutaneous T-cell lymphoma. J. Eur. Acad. Dermatol. Venereol. 17 (2003) 131–137. http://dx.doi.org/10.1046/j.1468-3083.2003.00635.x10.1046/j.1468-3083.2003.00635.xSearch in Google Scholar
[3] Willemze, R., Jaffe, E.S., Burg, G., Burg, G., Cerroni, L., Berti, E., Swerdlow, S.H., Ralfkiaer, E., Chimenti, S., Diaz-Perez, J.L., Duncan, L.M., Grange, F., Harris, N.L., Kempf, W., Kerl, H., Kurrer, M., Knobler, R., Pimpinelli, N., Sander, C., Santucci, M., Sterry, W., Vermeer, M.H., Wechsler, J., Whittaker, S. and Meijer, C.J.L.M. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768–3785. http://dx.doi.org/10.1182/blood-2004-09-350210.1182/blood-2004-09-3502Search in Google Scholar
[4] Neelis, K.J., Schimmel, E.C., Vermeer, M.H., Senff, N.J., Willemze, R. and Noordijk, E.M. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int. J. Rad. Oncol. Biol. Phys. 74 (2009) 154–158. Search in Google Scholar
[5] Kim, E.J., Hess, S., Richardson, S.K., Newton, S., Showe, L.C., Benoit, B.M., Ubriani, R., Vittorio, C.C., Junkins-Hopkins, J.M., Wysocka, M. and Rook, A.H. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J. Clin. Invest. 115 (2005) 798–812. Search in Google Scholar
[6] Diamandidou, E., Cohen, R.R. and Kurzrock, R. Mycosis fungoides and Sezary syndrome. Blood 88 (1996) 2385–2409. Search in Google Scholar
[7] Qin, J-Z., Dummer, R., Burg, G. and Dobbeling, U. Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells. Blood 93 (1999) 260–267. Search in Google Scholar
[8] Kari, L., Loboda, A., Nebozhyn, M., Rook, A.H., Vonderheid, E.C., Nichols, C., Virok, D., Chang, C., Horng, W.H., Johnston, J., Wysocka, M., Showe, M.K. and Showe, L.C. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J. Exp. Med. 197 (2003) 1477–1488. http://dx.doi.org/10.1084/jem.2002172610.1084/jem.20021726Search in Google Scholar
[9] Duvic, M. and Cather, J. Emerging new therapies for cutaneous T-cell lymphoma. Dermatol. Clin. 18 (2000) 147–156. Search in Google Scholar
[10] Querfeld, C., Rizvi, M.A., Kuzel, T.M., Guitart, J., Rademaker, A., Sabharwal, S.S., Krett, N.L. and Rosen, S.T. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J. Invest. Dermatol. 126 (2006) 1641–1647. http://dx.doi.org/10.1038/sj.jid.570032210.1038/sj.jid.5700322Search in Google Scholar
[11] Contassot, E. and French, L.E. Targeting apoptosis defects in cutaneous T-cell lymphomas. J. Invest. Dermatol. 129 (2009) 1059–1061. http://dx.doi.org/10.1038/jid.2009.1410.1038/jid.2009.14Search in Google Scholar
[12] Ni, X., Zhang, C., Talpur, R. and Duvic, M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J. Invest. Dermatol. 124 (2005) 741–750. http://dx.doi.org/10.1111/j.0022-202X.2005.23657.x10.1111/j.0022-202X.2005.23657.xSearch in Google Scholar
[13] Wu, J., Nihal, M., Siddiqui, J., Vonderheid, E.C. and Wood, G.S. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J. Invest. Dermatol. 129 (2009) 1165–1173. http://dx.doi.org/10.1038/jid.2008.30910.1038/jid.2008.309Search in Google Scholar
[14] Zhang, C.L., Kamarasher, J., Qin, J.Z., Burg, G., Dummer, R. and Dobbeling, U. Expression of apoptosis regulators in cutaneous T-cell lymphomas. J. Pathol. 200 (2003) 249–254. http://dx.doi.org/10.1002/path.134110.1002/path.1341Search in Google Scholar
[15] Takeda, K. and Akira, S. STAT family of transcription factors in cytokinemediated biological responses. Cytokine Growth Factor Rev. 11 (2000) 199–207. http://dx.doi.org/10.1016/S1359-6101(00)00005-810.1016/S1359-6101(00)00005-8Search in Google Scholar
[16] Bromberg, J. and Darnell, J.E.Jr. The role of STAT3 in transcriptional control and their impact on cellular function. Oncogene 19 (2000) 2468–2473. http://dx.doi.org/10.1038/sj.onc.120347610.1038/sj.onc.1203476Search in Google Scholar PubMed
[17] Levy, D.E. and Lee, C.K. What does Stat3 do? J. Clin. Invest. 109 (2002) 1143–1148. Search in Google Scholar
[18] Kortylewski, M., Jove, R. and Yu, H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 24 (2005) 315–327. http://dx.doi.org/10.1007/s10555-005-1580-110.1007/s10555-005-1580-1Search in Google Scholar PubMed
[19] Turkson, J. STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets 8 (2004) 409–422. http://dx.doi.org/10.1517/14728222.8.5.40910.1517/14728222.8.5.409Search in Google Scholar PubMed
[20] Sommer, V.H., Clemmensen, O.J., Nielsen, O., Wasik, M., Lovato, P., Brender, C., Eriksen, K.W., Woetmann, A., Kaestel, C.G., Nissen, M.H., Ropke, C., Skov, S. and Ødum, N. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18 (2004) 1288–1295. http://dx.doi.org/10.1038/sj.leu.240338510.1038/sj.leu.2403385Search in Google Scholar PubMed
[21] Nielsen, M., Kaltoft, K., Nordahl, M., Ropke, C., Geisler, C., Mustelin, T., Dobson, P., Svejgaard, A. and Ødum, N. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc. Natl. Acad. Sci. USA 94 (1997) 6764–6769. http://dx.doi.org/10.1073/pnas.94.13.676410.1073/pnas.94.13.6764Search in Google Scholar PubMed PubMed Central
[22] Zhang, Q., Raghunath, P.N., Xue, L., Majewski, M., Carpentieri, D.F., Ødum, N., Morris, S., Skorski, T. and Wasik, M.A. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol. 168 (2002) 466–474. Search in Google Scholar
[23] Eriksen, K.W., Kaltoft, K., Mikkelsen, G., Nielsen, M., Zhang, Q., Geisler, C., Nissen, M.H., Ropke, C., Wasik, M.A. and Ødum, N. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 15 (2001) 787–793. http://dx.doi.org/10.1038/sj.leu.240209310.1038/sj.leu.2402093Search in Google Scholar PubMed
[24] Michel, L., Dupuy, A., Jean-Louis, F., Sors, A., Poupon, J., Viguier, M., Musette, P., Dubertret, L., Degos, L., Dombret, H. and Bachelez, H. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J. Invest. Dermatol. 121 (2003) 881–893. http://dx.doi.org/10.1046/j.1523-1747.2003.12479.x10.1046/j.1523-1747.2003.12479.xSearch in Google Scholar PubMed
[25] Volkov, Y., Long, A., McGrath, S., Eidhin, D.Ni. and Kelleher, D. Crucial importance of PKC-β(I) in LFA-1-mediated locomotion of activated T cells. Nat. Immunol. 2 (2001) 508–514. http://dx.doi.org/10.1038/8870010.1038/88700Search in Google Scholar PubMed
[26] Verma, N.K., Dempsey, E., Conroy, J., Olwell, P., Mcelligott, A.M., Davies, A.M., Kelleher, D., Butini, S., Campiani, G., Williams, D.C., Zisterer, D.M., Lawler, M. and Volkov, Y. A new microtubule targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin. J. Mol. Med. 86 (2008) 457–469. http://dx.doi.org/10.1007/s00109-008-0312-810.1007/s00109-008-0312-8Search in Google Scholar PubMed
[27] Verma, N.K., Dourlat, J., Davies, A.M., Long, A., Liu, W.Q., Garbay, C., Kelleher, D. and Volkov, Y. STAT3-stathmin interactions control microtubule dynamics in migrating T-cells. J. Biol. Chem. 284 (2009) 12349–12362. http://dx.doi.org/10.1074/jbc.M80776120010.1074/jbc.M807761200Search in Google Scholar PubMed PubMed Central
[28] Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. and Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494–498. http://dx.doi.org/10.1038/3507810710.1038/35078107Search in Google Scholar PubMed
[29] Konnikova, L., Kotecki, M., Kruger, M.M. and Cochran, B. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 3 (2003) 23–32. http://dx.doi.org/10.1186/1471-2407-3-2310.1186/1471-2407-3-23Search in Google Scholar PubMed PubMed Central
[30] Gao, L.F., Xu, D.Q., Wen, L.J., Zhang, X.Y., Shao, Y.T. and Zhao, X.J. Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol. Sin. 26 (2005) 377–383. http://dx.doi.org/10.1111/j.1745-7254.2005.00053.x10.1111/j.1745-7254.2005.00053.xSearch in Google Scholar PubMed
[31] Grandis, J.R., Drenning, S.D., Zeng, Q., Watkins, S.C., Melhem, M.F., Endo, S., Johnson, D.E., Huang, L., He, Y. and Kim, J.D. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA 97 (2000) 4227–4232. http://dx.doi.org/10.1073/pnas.97.8.422710.1073/pnas.97.8.4227Search in Google Scholar PubMed PubMed Central
[32] Mora, L.B., Buettner, R., Seigne, J., Diaz, J., Ahmad, N., Garcia, R., Bowman, T., Falcone, R., Fairclough, R., Cantor, A., Muro-Cacho, C., Livingston, S., Karras, J., Pow-Sang, J. and Jove, R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62 (2002) 6659–6666. Search in Google Scholar
[33] Elmore, S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35 (2007) 495–516. http://dx.doi.org/10.1080/0192623070132033710.1080/01926230701320337Search in Google Scholar PubMed PubMed Central
[34] Reed, J.C. Bcl2 family proteins. Oncogene 17 (1998) 3225–3236. http://dx.doi.org/10.1038/sj.onc.120259110.1038/sj.onc.1202591Search in Google Scholar PubMed
[35] Osella-Aate, S., Zaccagna, A., Savoia, P., Quaglino, P., Salomone, B. and Bernengo, M.G. Expression of apoptosis markers on peripheral blood lymphocytes from patients with cutaneous T-cell lymphoma during extracorporeal photochemotherapy. J. Am. Acad. Dermatol. 44 (2001) 40–47. http://dx.doi.org/10.1067/mjd.2001.10837610.1067/mjd.2001.108376Search in Google Scholar PubMed
[36] Yu, H. and Jove, R. The STATs of cancer—new molecular targets come of age. Nat. Rev. Cancer 4 (2004) 97–105. http://dx.doi.org/10.1038/nrc127510.1038/nrc1275Search in Google Scholar PubMed
[37] Alshamsan, A., Hamdya, S., Samuel, J., El-Kadi, A.O.S., Lavasanifar, A. and Uludag, H. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 31 (2010) 1420–1428. http://dx.doi.org/10.1016/j.biomaterials.2009.11.00310.1016/j.biomaterials.2009.11.003Search in Google Scholar PubMed
[38] Yue, P. and Turkson, J. Targeting STAT3 in cancer: how successful are we? Expert Opin. Investig. Drugs 18 (2009) 45–56. http://dx.doi.org/10.1517/1354378080256579110.1517/13543780802565791Search in Google Scholar PubMed PubMed Central
[39] Cejka, D., Losert, D. and Wacheck, V. Short interfering RNA (siRNA): tool or therapeutic? Clin. Sci. (Lond.) 110 (2006) 47–58. http://dx.doi.org/10.1042/CS2005016210.1042/CS20050162Search in Google Scholar PubMed
[40] Grivennikov, S.I. and Karin, M. Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. (2009) in press. DOI:10.1016/j.cytogfr.2009.11.005. 10.1016/j.cytogfr.2009.11.005Search in Google Scholar PubMed PubMed Central
[41] Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., Kishimoto, T. and Akira, S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA 94 (1997) 3801–3804. http://dx.doi.org/10.1073/pnas.94.8.380110.1073/pnas.94.8.3801Search in Google Scholar PubMed PubMed Central
[42] de la Iglesia, N., Konopka, G., Lim, K.L., Nutt, C.L., Bromberg, J.F., Frank, D.A., Mischel, P.S., Louis, D.N. and Bonni, A. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J. Neurosci. 28 (2008) 5870–5878. http://dx.doi.org/10.1523/JNEUROSCI.5385-07.200810.1523/JNEUROSCI.5385-07.2008Search in Google Scholar PubMed PubMed Central
[43] Li, S.D., Chen, Y.C., Hackett, M.J. and Huang, L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther. 1 (2008) 163–169. http://dx.doi.org/10.1038/sj.mt.630032310.1038/sj.mt.6300323Search in Google Scholar PubMed PubMed Central
© 2010 University of Wrocław, Poland
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
